HIV Infections Clinical Trial
Official title:
Pain and Sensory Changes Assessment in HIV+ Patients, A Model for Pain and Sensory Changes Related Compromised Immune System.
There are about 42 million people in the world afflicted with HIV or AIDS with about 1
million patients in the US.
The epidemiology of orofacial pain has been reported extensively in the literature, yet the
prevalence severity and level of pain affecting the head, face, neck and intraoral
structures has not been explored in a population of HIV infected individuals.
Pain, in general terms, is a common experience in HIV infected patients, even in the absence
of cancer or opportunistic infections. There is a variation in the prevalence of pain in
these individuals depending on the stage of disease, care setting, and study methods. The
purpose of this study is:
1. To investigate the prevalence of orofacial pain in HIV infected patients during routine
dental clinical assessment.
2. To study the sensory phenotype of HIV+ patients and healthy volunteers using
Quantitative Sensory Testing:
- To detect the presence of sensory aberrations in the orofacial complex;
- To identify which nerve types are involved;
- To identify the type of orofacial pain based on both sensory testing and clinical
findings.
3. To determine psychological condition and nutrition status in patients with HIV.
4. To find associations between inherited traits and development of neuropathic pain.
Patients and control volunteers will be recruited from the Oral medicine Post-graduate
clinic at NJDS. Medical history will be taken and will include age, gender, ethnicity,
current and past illnesses, current and past medications, blood reports (CD4 and CD8 counts)
which have been obtained during routine medical assessment. The clinician will perform a
clinical head and neck examination. The examination shall include an extra-oral, cranial
nerve and temporomandibular joint (TMJ) examination, and muscle palpation. A thorough
intraoral examination will be performed. Patients will be examined for pathologies of the
oral mucosa, teeth and periodontium prior to their participation in the study. The
evaluation findings will be reported using the Research Diagnostic Criteria for
Temperomandibular disorders. The patient will note level of pain on Visual Analogue Scale if
there is any pre-existing orofacial pain. Psychological screening and nutritional
questionnaires will be completed by the patient.
Quantitative Sensory Testing will be conducted bilaterally on the face and intraorally on
the tongue. Extraorally, the infraorbital and mental nerves regions will be tested
bilaterally using thermal and electrical detection thresholds. Intraorally the tongue will
be tested bilaterally for thermal and electrical detection threshold.
Many of the differences among people in the way they respond to symptomatic therapies and
their individual risk of HIV+ patients with neuropathic pain may be affected by their
genetic makeup. We will search for these kinds of associations between inherited traits and
development of neuropathic pain in this study.
If the patient presents with evidence for pathologies that requires extraction of any molar
(based on clinical and radiographic findings), the patient will be assessed 3 days, 8 days
post-extraction and then after 3 weeks for thermal and electrical detection thresholds.
Inclusion criteria:
Group I n = 40 HIV+ with CD4+T cells/mm³ > 500 as determined by previous routine medical
examination and from previous blood reports.
Group II n = 40 HIV+ with CD4+T cells/mm³ 200-499 as determined by previous routine medical
examination and from previous blood reports.
Group III n = 40 HIV+ with CD4+T cells/mm³ < 200 as determined by previous routine medical
examination and from previous blood reports.
Control Group n = 40 Healthy with normal blood reports, without dental pathologies.
;
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |